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Thomas Greenough,b Barbara Tabak,c,d Manuel Garber,c,d Timothy F. Kowalik,a Katherine Luzuriagab,c
Department of Microbiology and Physiological Systems,a Department of Pediatrics,b Progam in Molecular Medicine,c and Department of Bioinformatics and Integrative
Biology,d University of Massachusetts Medical School, Worcester, Massachusetts, USA
ABSTRACT
We report the diversity of latent membrane protein 1 (LMP1) gene founder sequences and the level of Epstein-Barr virus (EBV)
genome variability over time and across anatomic compartments by using virus genomes amplified directly from oropharyngeal
wash specimens and peripheral blood B cells during acute infection and convalescence. The intrahost nucleotide variability of
the founder virus was 0.02% across the region sequences, and diversity increased significantly over time in the oropharyngeal
compartment (P 0.004). The LMP1 region showing the greatest level of variability in both compartments, and over time, was
concentrated within the functional carboxyl-terminal activating regions 2 and 3 (CTAR2 and CTAR3). Interestingly, a deletion
in a proline-rich repeat region (amino acids 274 to 289) of EBV commonly reported in EBV sequenced from cancer specimens
was not observed in acute infectious mononucleosis (AIM) patients. Taken together, these data highlight the diversity in circu-
lating EBV genomes and its potential importance in disease pathogenesis and vaccine design.
IMPORTANCE
This study is among the first to leverage an improved high-throughput deep-sequencing methodology to investigate directly
from patient samples the degree of diversity in Epstein-Barr virus (EBV) populations and the extent to which viral genome diver-
sity develops over time in the infected host. Significant variability of circulating EBV latent membrane protein 1 (LMP1) gene
sequences was observed between cellular and oral wash samples, and this variability increased over time in oral wash samples.
The significance of EBV genetic diversity in transmission and disease pathogenesis are discussed.
Epstein-Barr virus (EBV), a double-stranded DNA gammaher-pesvirus, infects more than 95% of the world’s population by
the 4th decade of life (1). Transmission occurs predominantly
through exposure to infected saliva. EBV persistence is lifelong
and is characterized by infection of epithelial tissues of the oro-
pharynx and circulating memory B cells (2, 3). Lytic infection of
epithelial and B cells results in the production of progeny viruses,
which are chronically shed at high levels (average,104 particles/
ml) in saliva (4, 5). Latently infected memory B cells serve as a viral
reservoir in which EBV evades immune surveillance through the
transcription of a restricted subset of viral genes and limited pro-
tein expression (6).
While most EBV infections are asymptomatic, primary infec-
tion in late childhood or after the 2nd decade of life may result in
acute infectious mononucleosis (AIM). In addition, EBV has been
associated with epithelial and lymphoid malignancies. Character-
ization of the sequences of infecting strains of EBV, and of the
diversity and stability of the viral genome over time, would con-
tribute to the development of a prophylactic vaccine (7). Exami-
nation of EBV genetic diversity over time in healthy and diseased
hosts may also improve insights into the transforming properties
of EBV (6, 8) that could allow the development of improved ther-
apies for EBV-associated malignancies.
Prior studies have relied primarily on analyses of restriction
fragment length polymorphisms or EBV nuclear antigen (EBNA)
protein length variations (“EBNotype”) of EBV strains to evaluate
the genetic diversity of individual EBV genes in oropharyngeal
secretions, peripheral blood, and tumor tissues. Collectively, these
data reveal diversity in 6 genes (EBNA 1, EBNA 2, EBNA 3A,
EBNA 3B, EBNA 3C, and latent membrane protein 1 [LMP1])
important in the establishment and maintenance of the virus in B
lymphocytes (9–12). However, these assays are more qualitative
than quantitative. More-recent studies have employed PCR-based
analyses (heteroduplex tracking assays or cloning and Sanger se-
quencing) to demonstrate particular heterogeneities of LMP1 se-
quences (13, 14).
While EBV polymorphisms have been described, the diversity
of circulating EBV strains remains poorly defined. Whole-genome
sequences are available for only a limited number of primary vi-
ruses (15). We and others have previously shown significant dif-
ferences in sequence and in vitro functional properties between
viruses propagated in vitro and those sequenced directly from pe-
ripheral blood or body fluids (e.g., HIV and human cytomegalo-
virus [HCMV] [16–19]). Moreover, sequencing of tumor-associ-
ated viruses may select EBV strains with enhanced transforming
properties for analysis (20–27).
High-throughput sequencing is a powerful tool for examining
viral diversity directly from patient samples. These methods offer
the ability to accurately quantify viral variants at the initiation of
infection and to track the evolution of the quasispecies over time
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(19). They also offer unique challenges, most notably distinguish-
ing between true viral diversity and sequencing error (28, 29) and
correctly characterizing complex population structures (30, 31).
We have previously developed Illumina deep-sequencing proto-
cols to perform genomewide sequencing of HCMV (18). Those
studies showed that HCMV populations are highly diverse, with
levels of nucleotide variation comparable to those previously de-
scribed for RNA viruses, such as dengue virus and HIV (18). Oth-
ers have shown that viral diversity is correlated with pathogenesis
in both DNA and RNA viruses (16, 17, 32), while we have shown
that viral diversity can contribute to rapid evolution in human
hosts (19).
In the present study, we have applied high-throughput se-
quencing to investigate directly from patient samples the degree of
diversity in founder virus populations and the extent to which
EBV genome diversity develops over time in the infected host.
Since whole-genome sequencing requires relatively large volumes
of blood (especially during chronic infection, when circulating
memory B cell frequencies are low), we targeted LMP1 for ampli-
fication and sequencing. LMP1 is an integral transmembrane pro-
tein with relatively high genetic diversity, functional importance,
and a large number of known CD8 T cell epitopes (33–39). It
consists of a short amino-terminal cytoplasmic tail (amino acids
[aa] 1 to 25), six transmembrane domains (aa 26 to 196), and a
carboxyl-terminal tail (aa 197 to 386). The C terminus contains 3
functional domains (carboxyl-terminal activating regions 1, 2,
and 3 [CTAR1, -2, and -3]) that interact with cellular proteins to
activate a wide array of signaling pathways, including nuclear fac-
tor B (NF-B), and cell cycle-regulatory molecules (20, 22, 40–
42).
In this study, we specifically analyzed the EBV LMP1 gene pres-
ent in latently infected B cells (BC) as well as in virus shed from
infected oropharyngeal epithelial cells (oral wash [OW] samples)
during AIM and 6 months postinfection (convalescence [CONV]).
Significant interhost and intrahost variability of circulating EBV
LMP1 sequences was observed over time and between anatomic
compartments. The potential importance of the genetic variability
observed for EBV transmission and disease pathogenesis is dis-
cussed.
MATERIALS AND METHODS
Study population and specimens. The Institutional Review Board of the
University of Massachusetts Medical School approved these studies, and
all participants provided written informed consent. Blood and oropha-
ryngeal samples were obtained from a previously described cohort of
young adults (44, 45) who presented with symptoms of AIM, which was
further confirmed by a positive monospot (heterophile antibody) assay.
Primary EBV infection was confirmed by the detection of serum IgM
antibodies at presentation, along with the development of serum IgG
antibodies in convalescence, to the EBV viral capsid antigen. Paired blood
and oropharyngeal samples were again collected 6 months after presenta-
tion with AIM (i.e., during convalescence [CONV]).
B cell purification and DNA isolation. B cells were purified (95%)
from whole blood using the RosetteSep human B-cell enrichment cocktail
and the manufacturer’s protocol (StemCell Technologies, Vancouver,
BC, Canada). DNA was extracted using Qiagen (Valencia, CA) DNeasy
Mini spin 150 columns. DNA from oral wash samples was isolated using
the Roche (Indianapolis, IN) High Pure viral nucleic acid kit, and viral
loads were measured using the Roche (Indianapolis, IN) LightCycler EBV
quantitation kit by quantitative PCR (qPCR) on the Roche LightCycler
system (44, 45).
Amplification of EBV genomic DNA. Overlapping PCRs were per-
formed using primer pairs that were designed specifically to optimize the
amplification of EBV LMP1 (primers 165342F [5=-ACGGCAACTACCT
GTGCCGC-3=] and 167810R [5=-ATGGCGGCGGTGATCCACAC-3=]
for reaction A and primers 166820F [5=-TGG TCTACCCGGTCGCATG
G-3=] and 169603R [5=-ACACTCGCACAGCCCACACC-3=] for reaction
B). These primers were also used to amplify the identical region of the type
I strain of EBV, B95-8, from a previously described bacterial artificial
chromosome (BAC) construct (46) (kindly provided by Fred Wang).
Library construction and Illumina sequencing. The amplicon DNA
was processed for analysis by Illumina sequencing as described previously
(18). The ends of the Bioruptor-fragmented DNA segments were repaired
(Epicentre end repair kit); adapters with appropriate bar codes were li-
gated; and a library with a median size of 300 bp 50 bp was produced.
The library was amplified with Illumina paired-end primers and was then
sequenced (UMMS Deep Sequencing Core). The reads were sorted by bar
code, after which the bar code sequence was removed. Raw Illumina se-
quence reads were deposited to the NCBI Sequence Read Archive (SRA)
and are associated with BioProject PRJNA231919.
Sequence data analysis: alignment, coverage, filtering process, and
variant selection.An analysis pipeline, similar to that reported previously
(18, 47), provided a computationally expedient framework for the extrac-
tion of information from the large data set. The development and valida-
tion of the pipeline depended on resequencing of the LMP1 region of an
EBV B95-8 BAC. After removal of the adapter sequences, a consensus
sequence was called for each sample on the basis of de novo contig assem-
bly with the SSAKE program (48), followed by full-length sequence as-
sembly with the assembly algorithm of the Geneious software suite (Ge-
neious, version 4.8; created by Biomatters). The full-length consensus
sequences were then used to identify polymorphisms and insertions/de-
letions (indels) between patient samples. The full-length consensus se-
quence was also used for reference-guided alignment to call intrahost
variants (49). Variants from the reference sequence were called using a
variant-filtering algorithm described previously (18, 47). This algorithm
determines those putative polymorphisms that are likely to be “true” vari-
ants on the basis of base call quality, mapping quality, local depth, variant
frequency, and variant count. The threshold values for these parameters
were selected empirically to balance sensitivity and specificity based on
our sequence data for the B95-8 BAC. Variants included in downstream
analysis have base call qualities of30, mapping qualities of89, a local
depth of15, variant counts of3, and a variant frequency of1.86%.
The false-positive rate (the rate of inclusion of errors in the sequence data)
is highly dependent on the frequency threshold used in the filtering algo-
rithm as well as on the sequencing depth. In this study, we have achieved
an average depth of 52,000 times for the samples, with a minimum depth
of 6,000 times. We used a minimum variant frequency threshold of
1.86%, leading to a maximum false-positive rate of 1% across all samples.
This threshold is similar to those that we and others have reported previ-
ously (18, 19).
Data from the variant filter were then further processed to calculate
nucleotide diversity (), mean diversity, inferred amino acid diversity,
and the ratio of nonsynonymous to synonymous substitutions (dN/dS).
JalView (50) was used to visualize the amino acid sequence alignment and
to determine conservation histograms, columns with mutations, and col-
umns with conserved physicochemical properties. Quantitative analysis
of the alignment yielded a numerical index score based on conserved
physicochemical properties for each column as described by Livingstone
and Barton (51).
Nucleotide sequence accession numbers. Consensus sequence data
from this study have been deposited in the NCBI database under accession
numbers KF871337 to KF871363.
RESULTS
False-positive rate in deep-sequencing data as a function of
depth and the variant frequency threshold. EBV BAC B95-8
EBV LMP1 Genetic Variability
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DNA was PCR amplified and was processed as a template for
amplification and paired-end sequencing on the Illumina GAII
system in order to estimate the background error rate (see Mate-
rials and Methods). The output was 108 Mb of EBV sequence, or
the equivalent of approximately 466 EBV genomes. A key param-
eter of the filtering is a frequency threshold, such that all variants
below the frequency threshold are excluded from the analysis. In
this study, we achieved nearly 100% coverage for all samples, with
a minimum depth of 3,500 times, an average depth of 52,000
times, and a minimum variant frequency threshold of 1.86%,
leading to a maximum false-positive rate of 1% across all samples
(Table 1).
Intrahost nucleotide and amino acid diversity. The intrapa-
tient nucleotide diversity () of LMP1 populations was calculated
using the formula described previously (52). The  value mea-
sures the average pairwise difference between any two sequences
within a sample and allows for the assessment of genetic variation
within a set of samples, since increasing  values correspond to
increasing genetic variation of a population. Samples were
grouped by compartment (BC, OW) or time (AIM, CONV) in
order to analyze diversity patterns. The average nucleotide value
of the lmp1open reading frames of all samples present in our study
was 0.02% (Table 1 and Fig. 1). Overall, nucleotide diversity in
samples during primary infection (AIM) (, 0.01%) was lower
than that in convalescent-phase samples (CONV) (, 0.03%);
greater diversity was observed in the OW samples (, 0.025%)
than in BC (, 0.012%).
The intrahost nucleotide diversity of all B cell and OW samples
was low in AIM (,0.015% and0.01%, respectively), suggest-
ing that the founder virus was relatively homogenous. Diversity
increased significantly in oral wash samples during CONV (,
0.04%), while it remained low in B cells (, 0.01%) (Fig. 1).
Indeed, the diversity of EBV genomes in oral wash samples during
CONV was significantly greater than that in all other samples (P,
0.004 by the Kruskal-Wallis test with the Bonferroni-Dunn post
hoc test). Kruskal-Wallis analysis of the diversity across all 4 com-
binations of compartments and times (B cells during AIM, B cells
during CONV, OW samples during AIM, and OW samples during
CONV) showed a significant difference (P, 0.004), but with only 3
combinations (B cells during AIM, B cells during CONV, and OW
TABLE 1 Sequence reads, sequencing depths and coverage, and intrahost diversity
Patient
Sample source
and time
No. of
reads (107)
No. of
sequences
generated (108)
Avg sequencing
depth (times)
%
Coverage
No. of
variable
sites
Nucleotide
diversity ()
(%)
No. of
nonsynonymous
variants AA
a (%)
B95-8 BAC 3.95 13 72,174 100
E1347 BC.AIM 1.04 3.44 9,782 100 23 0.287 18 0.242
OW.CONV 0.786 2.59 5,071 99.96 71 0.205 48 0.145
E1369 OW.AIM 1.60 5.28 90,111 100 6 0.066 6 0.066
BC.AIM 1.20 3.96 46,850 100 0 0.000 0 0.000
BC.CONV 1.04 3.42 8,369 100 5 0.064 5 0.064
E1376 OW.AIM 0.976 3.22 38,612 100 0 0.000 0 0.000
BC.AIM 2.90 9.57 75,689 100 0 0.000 0 0.000
E1405 OW.AIM 1.23 4.08 93,015 100 0 0.000 0 0.000
BC.AIM 1.16 3.84 48,731 100 0 0.000 0 0.000
OW.CONV 0.768 2.53 57,191 100 0 0.000 0 0.000
BC.CONV 1.02 3.38 3,562 100 1 0.016 0 0.000
E1420 OW.AIM 1.33 4.39 88,987 100 1 0.020 0 0.000
BC.AIM 1.83 6.02 101,346 100 1 0.013 0 0.000
OW.CONV 0.889 2.94 67,005 100 0 0.000 0 0.000
BC.CONV 0.115 0.379 4,849 100 1 0.008 0 0.000
E1435 OW.AIM 0.946 3.12 55,378 99.96 1 0.009 1 0.009
BC.AIM 0.452 1.49 7,619 100 5 0.052 5 0.052
OW.CONV 0.099 0.327 3,959 100 6 0.052 5 0.050
E1458 OW.AIM 0471 1.55 28,433 100 0 0.000 0 0.000
E1471 OW.AIM 1.75 5.78 49,849 100 1 0.006 0 0.000
BC.AIM 1.45 4.79 15,625 100 0 0.000 0 0.000
OW.CONV 2.03 6.71 56,322 99.96 1 0.007 0 0.000
BC.CONV 0.929 3.07 15,183 100 1 0.012 0 0.000
E1475 OW.AIM 2.02 6.68 129,393 100 1 0.002 0 0.000
BC.AIM 1.29 4.27 38,843 100 0 0.000 0 0.000
OW.CONV 2.30 7.58 119,234 100 31 0.140 23 0.098
BC.CONV 0.956 3.15 8,083 100 1 0.002 0 0.000
a AA, amino acid diversity.
Renzette et al.
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samples during AIM), the difference was not significant (P, 0.52).
However, when these combinations were pooled (B cells during
AIM, B cells during CONV, and OW samples during AIM), the
difference from OW samples during CONV was significant by the
Mann-Whitney test (P, 0.0004). Furthermore, instead of grouping
the samples according to sampling time or source, the median
nucleotide diversity ( score) for each patient sample was plotted
in order to analyze patterns, albeit with less power to detect dif-
ferences (Fig. 1, inset). A Mann-Whitney analysis of the diversity
of samples with time and compartment suggested a trend (P,
0.086) toward greater diversity in OW samples during CONV
than in OW samples during AIM.
Population differentiation across time and compartment.
To measure the extent of divergence among populations rela-
tive to the net genetic diversity, FST (fixation index) was calcu-
lated for all pairs of samples across time or compartments for
each patient (Fig. 2). FST, a commonly used metric, is a measure
of population differentiation bounded by 0 and 1; higher values
indicate greater variation in single nucleotide polymorphism
(SNP) frequency between populations and, thus, higher levels
FIG 1 Intrahost nucleotide diversity () by sample timing and compartment. Samples were grouped by time or compartment in order to analyze patterns of
diversity, and results were plotted as points. Black horizontal lines indicate mean values. The diversity of OW samples taken during convalescence (OW.CONV)
is statistically significantly higher than the diversities of all other samples (P, 0.004 by the Kruskal-Wallis test with the Bonferroni-Dunn post hoc test). Data on
all individual samples can be found in Table 1. (Inset) The mean nucleotide diversity for each patient sample taken at the indicated time (AIM or CONV) from
the indicated compartment (B cells, OW) was plotted in order to analyze patterns. Horizontal lines indicate mean nucleotide diversity for each timepoint (AIM
or CONV) and compartment (B cells, OW) from matched patient samples. Filled circles, B cells in AIM; upright triangles, B cells in CONV; filled squares, oral
wash samples in AIM; inverted triangles, oral wash samples in CONV.
FIG 2 Population differentiation across times and compartments. FST was
calculated for all pairs of samples across times or compartments for each pa-
tient. The values of FST were then grouped by time or compartment and were
plotted as points. Horizontal lines indicate means.
EBV LMP1 Genetic Variability
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of population differentiation. FST was calculated, as described
previously (47), for all longitudinal or compartmental pairs of
samples. The values of FST were then grouped by time or com-
partment and are presented as scatter plots, with the mean
values shown as black lines (Fig. 2). The average FST value
across all samples was 0.10 (zero indicates no divergence), sug-
gestive of a low to moderate degree of population differentia-
tion between samples. However, there was little difference in
values when they were compared across time or across com-
partments, suggesting that differentiation is not dependent on
these parameters. No significant evidence of positive selection
in gene sequences was observed by the method of Nielsen et al.
(53) (data not shown). These data, along with those presented
in Fig. 1, show that while intrahost LMP1 sequences are diverse,
the specific collection of mutations that occur within a single
host is established during primary infection and is fairly stable
over the sampling period (6 months) in this study.
The average amino acid  value of LMP1 for all samples pres-
ent in our study was 0.03% (Table 1). To determine the intrahost
amino acid variability found throughout the primary sequence of
LMP1, the frequency of variation was charted for each amino acid
position in LMP1. High (1%) sequence diversity was observed
in four AIM patients (Fig. 3). Overall, three distinct patterns were
observed in these patients. First, in patients E1435 and E1369,
high-frequency variants clustered between amino acids 260 and
360 (Fig. 3, top). Second, a pattern of low-frequency variation was
found throughout the primary sequence of the protein, as dem-
onstrated by samples from patient E1475 (Fig. 3, bottom). The
third pattern, which is a hybrid of patterns 1 and 2, is evident in
samples from patient E1347. We used previously reported geno-
typing information (27, 41, 54) to determine whether these sites
were informative of the presence of one or several previously iden-
tified LMP1 genotypes. Only a very small proportion of the amino
acid variable sites were genotype informative (6 of 66 for E1347, 1
of 11 for E1435, 1 of 23 for E1475, and none for the other patients),
suggesting that genotype classification schemes poorly character-
ize the variability that exists within in vivo EBV populations.
Interhost nucleotide and amino acid diversity: phylogeny
and protein alignment. To examine interhost genetic variability
and evolutionary relationships, patient LMP1 gene sequences
were analyzed by constructing a maximum likelihood tree (Fig. 4).
LMP1 gene sequences from type I (B95-8, GD1, GD2, Akata, and
Mutu) and type II (AG876) strains, as well as LMP1 sequences
obtained from specific geographical regions (China 1, China 2,
Mediterranean  [Med], Med	, North Carolina [NC], and
Alaskan sequences), were also included. All samples from the
same patient/host were highly similar and clustered together, re-
gardless of time point or compartment of origin. Samples from
three patients (E1376, E1471, and E1420) were most closely re-
lated to the prototypical type I strain B95-8, isolated from a patient
with infectious mononucleosis. The remainder of the cohort dem-
onstrated greater similarity to other reference LMP1 sequences.
For example, E1347 samples appeared to be most closely related to
a cluster that contained both type I (Med, Mutu) and type II
FIG 3 Intrahost amino acid variability in LMP1 sequences from the samples of four AIM patients. Shown are the frequencies of sequences from four patients that
exhibited intrahost LMP1 amino acid variability of1%. Three patterns of variability were observed. In the first, high-frequency variants are clustered between
amino acids 260 and 360. This pattern is seen in samples from patients E1435 and E1369. The second pattern features low-frequency variation found throughout
the primary sequence of the protein, as demonstrated by the sample from patient E1475. The third pattern, a hybrid of patterns 1 and 2, is evident in patient
sample E1347. Open circles, BC during AIM; filled circles, BC during CONV; open squares, OW samples during AIM; filled squares, OW samples during CONV.
Renzette et al.
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(AG876) LMP1 sequences. Samples from four other patients
(E1458, E1369, E1405, and E1475) aligned better with a cluster
containing Akata, GD1, GD2, and China 1 sequences.
A principal component scatterplot of patient samples and
B95-8 was created with data specifying the nucleotide contents of
variant positions relative to B95-8, as also called by the Genome
Analysis Toolkit (GATK) (55) (data not shown). Samples from
the same patient clustered together but failed to indicate a rela-
tionship between the patient LMP1 sequence and the calendar
time of infection, HLA type, or clinically available information.
Amino acid and protein alignments of LMP1 sequences of
patient samples with LMP1 sequences of reference strains. To
identify potential selective pressures that might result in LMP1
diversity in our patient cohort, we looked for specific mutations at
the amino acid level in regions of functional significance. To that
end, a full-length LMP1 protein consensus sequence from each
patient was aligned with a consensus sequence generated from all
reference and patient sequences (Fig. 5). The alignment showed
areas of interpatient variation where residues differ from the total
consensus sequence, along with regions of high conservation, i.e.,
either with no change in residue or with conservation of polarity/
charge. The N-terminal cytoplasmic tail, to which no specific
function has been attributed, displayed almost complete conser-
vation across our patient samples. A notable exception was the
consensus sequence of patient E1475, which differed from the
other patient samples at four positions in the cytoplasmic region
(specifically, aa 3, 13, 17, and 25); however, all four variant resi-
dues were present in at least half of the reference samples (Akata,
Alaskan, China 1, China 2, GD1, and GD2), and three were ob-
served to be present in LMP1 sequenced from a nasopharyngeal
carcinoma (NPC) patient from North Carolina (NC). Similarly,
analysis of the transmembrane domain of LMP1, contained
within residues 25 to 186 of the protein, demonstrated less diver-
sity in patient samples than in reference samples. The majority of
the amino acid variation in the transmembrane domain of patient
LMP1 sequences was restricted to only 14 total positions spread
across the 160-aa region, compared to 29 positions in reference
samples. In patient samples, amino acid substitutions at these po-
sitions were functionally conserved and were evenly represented
in the samples, e.g., the Leu residue at 122 was observed in half of
the patient samples (E1369, E1405, E1435, E1458, and E1475) or
was replaced with Ile (E1347, E1376, E1420, and E1471). As with
the LMP1 cytoplasmic tail region, almost all variants present in
the patient samples were observed in at least one of the reference
samples, with two notable exceptions. The amino acid sequence of
patient E1376 displayed a functionally conserved Leu substitution
at Ile78, which was unique among all samples. An additional,
more dramatic substitution (Gly at Arg133) was observed in three
patient samples (E1369, E1405, and E1458); this amino acid was
not present in any of the reference sequences.
In contrast to the findings for the cytoplasmic tail and trans-
membrane regions of LMP1, analysis of the CTARs revealed sub-
stantial variability in amino acids between patient and reference
samples. Reference samples showed remarkable conservation in
CTAR1 (aa 192 to 234), with only two positions, Ser212 and
Ser229, displaying variation from the consensus sequence, al-
though these variants maintained either size (Gly) or side chain
reactivity (Thr). Variants at both of these residues were also ob-
served, separately, in patient samples E1347 and E1376. Addi-
tional alternative amino acids were determined to be present in
the CTAR1 of several patient samples (E1347, E1420, E1458, and
E1475) and not in any of the reference samples. The C-terminal
region of the protein, containing a portion of CTAR2 (aa 351 to
386), displayed a high degree of conservation, as demonstrated by
the presence of only a few, sporadic variants in both reference and
patient samples. A greater degree of variation was observed in the
N-terminal portion of this domain; indeed, the greatest levels of
LMP1 variability in our patient samples were determined to be
concentrated between the C terminus of CTAR1 and the N termi-
nus of CTAR2, in the span containing CTAR3 (Fig. 5 and 6).
As noted above and as seen in Fig. 3 and 5, the region where
high-frequency variants clustered was between amino acids 260
and 360 and corresponded to the signaling domains overlapping
CTAR3 and CTAR2. To identify specific variations within this
region, the protein alignment of LMP1 sequences from study pa-
tients was compared with reference EBV LMP1 sequences and
with the consensus sequence derived from all reference and pa-
tient samples (Fig. 6). Comparison of CTAR3 and a significant
portion of CTAR2 of the consensus LMP1 sequences from our
patient samples demonstrated considerable variability; the nine
patient samples segregated into 6 distinct groups. Three groups
consisted of two patient sequences (E1369 and E1405; E1420 and
E1471; E1458 and E1475), while the remaining three patient sam-
ples each formed a distinct group (E1347, E1376, and E1435). Five
of these groups were unique and did not match any of the refer-
ence samples used in our analysis, while the remaining patient
sample (E1376) aligned with the LMP1 reference sequence from
B95-8. The LMP1 consensus sequence from patient E1435 dis-
played the greatest variability among all patient samples, contain-
ing substitutions observed in other patient and reference samples
FIG 4 Phylogenetic analysis of patient LMP1 sequences. Shown is a maximum
likelihood tree constructed using patient LMP1 consensus sequences as well as
sequences from a prototypic EBV type I strain (B95-8) and from type I (Akata,
Mutu, GD1, GD2) and type II (AG876) reference sequences associated with
distinct geographical locations. Nodes with 90% bootstrap support are la-
beled.
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FIG 5 Amino acid alignment of LMP1 sequences from reference strains and patient samples. Each patient is represented by a single sample. Conservation
histograms, with numerical index scores reflecting conserved physicochemical properties for each column of the alignment, based on the method of Livingstone
and Barton (51), are shown. Conserved columns are indicated by asterisks (score of 11 with default amino acid property grouping), and columns with mutations
where all properties are conserved are marked with plus signs (score of 10, indicating that all properties are conserved).
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(e.g., Gln276, present in AG876, Alaskan, China 2, Med, Med	,
and NC sequences; Gln 322, present in E1376, E1420, and E1471
as well as in B95-8 and China 2 sequences). This patient’s consen-
sus sequence also displayed several unique amino acids substitut-
ing Asn for Asp at position 317 of the protein, Asp for Gly (at aa
319), and Cys for Gly (at aa 355); usage of these amino acids was
not observed in any other patient or reference sequences used in
our analysis.
In addition to alternative amino acid usage, our patient sam-
ples also displayed variability in overall LMP1 sequence length in
this region, particularly in comparison to LMP1 reference se-
quences. With the notable exception of B95-8, all reference sam-
ples displayed a previously described deletion of 5 to 15 amino
acids in CTAR3 (aa 274 to 289) (11). In contrast, consensus se-
quences from our patient samples lacked this deletion in CTAR3,
although two patient samples (E1347 and E1435) did contain a
minimal deletion of 2 residues in this region (Fig. 6, bottom align-
ment). A separate sequence length variant, resulting from the in-
sertion of a 10-amino-acid repeat between residues 342 and 355,
spanning the N-terminal region of CTAR2, was present in about
FIG 6 Protein alignment of LMP1 sequences from study patients with reference EBV LMP1 sequences. A conservation histogram, with numerical index scores
reflecting conserved physicochemical property scores as described in the legend to Fig. 5, is shown below the top alignment. The top alignment includes both
reference sequences and a single representative for each patient, with any positions of intrapatient variability marked by a caret both above the alignment and
within the applicable sequence. The bottom alignments include the sequences for all samples of patients with any intrapatient variability in the corresponding
regions. A filled triangle marks each of the three positions where multiple patients have intrapatient variability. At two of these positions, two patients exhibit the
same deviation from B95-8 in one or both oral wash (OW) samples.
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half of the reference samples (B95-8, Alaskan, China 2, Med	,
Mutu, and NC samples) as well as in 7 of 9 patient samples (E1347,
E1376, E1420, E1471, E1435, E1458, and E1475).
Two alleles differing within the highly variable CTAR2–
CTAR3 sequence were of particular interest, since they showed
similar compartmental patterns in two different patients. Two
patients (E1405, E1435) showed a His (major allele in BC sam-
ples)-to-Glu (major allele in OW samples) substitution at aa 276.
Similarly, we observed an allele change in two different patients
(E1347, E1435) involving a His (BC samples)-to-Arg (OW sam-
ples) substitution at aa 352. We also noted a significant amino acid
substitution in this region for patient E1435 samples, in which the
conserved hydrophobic residue at position 355 (either Gly, Ala, or
Val) had been replaced with Cys.
DISCUSSION
We sequenced the EBV LMP1 gene present in latently infected B
cells (BC), as well as in virus shed from the oropharyngeal com-
partments (oral wash [OW] samples), of infected individuals dur-
ing acute infectious mononucleosis (AIM) and 6 months postin-
fection (during convalescence [CONV]) in order to determine the
interhost and intrahost variability of circulating EBV LMP1 se-
quences. Our results suggest the presence of considerable interpa-
tient viral genome diversity in circulating EBV strains. Viral diver-
sity in BC and OW samples was lower during acute infection;
diversity increased over the course of EBV infection, particularly
in infected epithelial tissue. In addition, our results suggest qual-
itative differences between sequences of viral proteins produced
during the EBV infectious cycle and reported sequences from tis-
sues of individuals with EBV-associated disease. To our knowl-
edge, this is among the first studies to leverage deep-sequencing
technology to quantitatively measure the genomic diversity of cir-
culating EBV strains.
Intrahost genetic variability was observed in EBV-infected in-
dividuals. Our previous work has shown that the diversity of
HCMV, a DNA virus, is comparable to that observed in popula-
tions of RNA viruses, such as dengue virus (18). As Table 1 and
Fig. 1 demonstrate, the average overall intrahost variability of EBV
sampled from human hosts in our study was 0.02%. This value is
comparable to the whole-genome variability seen in early infec-
tion with RNA viruses such as West Nile virus (0.03%) and HIV-1
(0.04%) (17, 21, 30, 31), although it is approximately 10-fold
lower than that of HCMV (0.21%) or dengue virus (0.3%) popu-
lations characterized in early infection. RNA viruses, such as hep-
atitis C virus (HCV) or HIV-1, have been shown to harbor high
levels of genetic diversity (56–59), presumably due to high muta-
tion rates intrinsically associated with RNA replication or reverse
transcription (60). It is becomingly increasingly apparent that
DNA viruses may also exhibit significant intrahost diversity. For
example, significant population variability has been observed in
pseudorabies virus (61), HCMV (18), and Kaposi’s sarcoma-as-
sociated herpesvirus (KSHV) (62), members of the alpha-, beta-,
and gammaherpesviruses, respectively. Our results extend these
findings and suggest that this is a general phenomenon of the
Herpesviridae family, although the factors contributing to the di-
versity remain unclear. Population bottlenecks associated with
transmission and dissemination have been described in RNA vi-
ruses, such as HIV-1 (63), and, to a lesser extent, in DNA viruses
(64), including the herpesvirus HCMV (19). The mutation rates
of DNA viruses, and of herpesviruses specifically, are significantly
lower than those of RNA viruses (65).
The relatively limited overall genomic diversity of EBV in acute
infection suggests the possible selection of variants for transmis-
sion or for amplification posttransmission. In this study, we also
documented a distinct increase in the genomic diversity of EBV in
the OW samples of our cohort at time points between 6 months
and a year after initial infection. In contrast, the viral genomic
variability present in the B cell compartment of our cohort was
determined to be very low. These findings are compatible with the
notion that LMP1 variance is introduced during the replication of
the viral genome during particle production in the oropharynx.
This observation is consistent with our current understanding of
the EBV replication cycle and of the requirement for LMP1 func-
tionality in establishing latent EBV infection in B cells. The low
level of genomic variation measured in the B cell compartment at
both time points further suggests that seeding of B cells by viruses
produced by the host is infrequent, at least over the limited time
course (6 months to 1 year) under investigation.
Although the overall level of EBV genomic nucleotide varia-
tion in B cells was determined to be low, analysis of LMP1 at the
amino acid level indicated the presence of allelic variants not pres-
ent in virus from oral wash samples in several patients. Samples
from patients E1347, E1405, and E1435 displayed differences in
the major alleles present in the two compartments, notably at
His276 and His352, as well as at Gly355. In all cases, the substitu-
tion was relatively modest (Glu for His at aa 276, Arg for His at aa
352, and Cys for Gly at aa 355), however, and these alleles did
appear to segregate by compartment, with Glu, Arg, and Cys sub-
stitutions appearing in samples derived from oral washes.
Whether these substitutions provide further evidence for an in-
crease in genome diversity generated during transcription or
whether they indicate selected colonization of compartments dur-
ing infection remains to be determined.
To date, only a few full-length EBV genomic sequences are
available, and most EBV genotyping was done prior to the avail-
ability of next-generation sequencing. Moreover, many available
sequences were derived from patients diagnosed with diseases as-
sociated with EBV infection (i.e., Burkitt’s lymphoma or NPC)
and may not adequately reflect viral genomes in circulation. These
sequences have also been identified as potentially endemic to spe-
cific geographic regions (e.g., GD1, GD2, China 1, and China 2).
In contrast to this notion, our maximum likelihood tree demon-
strated that while the sequences of samples from each individual
patient in our cohort taken at different time points or from differ-
ent compartments clustered with each other, their sequences clus-
tered with LMP1 sequences from a range of geographic isolates.
This finding suggests that the overall diversity of EBV circulating
within a population may be sizeable.
While polymorphisms in various EBV genes have been identi-
fied, the factors contributing to genetic variability are not well
understood. Low but detectable genomic diversity at presentation
with symptoms of AIM suggests the transmission of more than
one variant. Alternatively, diversity may result from the transmis-
sion of a single variant followed by early intrapatient diversifica-
tion. While EBV polymerase has proofreading activity, the de-
tection of sequence diversity in AIM (i.e., several weeks
postexposure) could have resulted from high-level ongoing viral
replication coupled with intrapatient selective pressures (e.g., viral
tropism, viral replication fitness, host immune responses). Re-
Renzette et al.
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peated infection (“reinfection”) over time may also contribute to
EBV diversity, as reported in an LMP1 genotype study (23, 24, 27).
The data presented in Fig. 1 and 2 (particularly the OW sample
data) support a model of intrapatient diversification due to viral
replication or other mechanisms and are not consistent with a
reinfection model. However, our data are based on limited (6
months) longitudinal follow-up samples. Additional sampling
time points and the analysis of larger genomic loci are necessary.
Altogether, however, the observed interhost and early intrahost
variability may pose a significant challenge for the development of
prophylactic vaccines against EBV.
Better understanding of factors contributing to genetic diver-
sity is important. Of interest is that we detected previously de-
scribed CD8T cell escape mutations in AIM patient samples (54,
66), specifically the peptide YLL (YLLEMLWRL), which was iden-
tified previously as the major HLA-A2-restricted cytotoxic T lym-
phocyte (CTL) epitope in LMP1. Three of the nine patients
(E1376, E1420, and E1471) had the wild-type (prototypic) B95-8
sequences for the YLLEMLWRL epitope at early and late time
points, both in BC and in OW samples. Sequences from four of the
remaining patients (E1369, E1405, E1458, E1475) showed a sub-
stitution in the A2 anchor residue at position 2 (L126F), expected
to alter major histocompatibility complex (MHC) class I binding.
Duraiswamy et al. (67) reported that this substitution is present in
LMP1 genes of healthy individuals and in NPC biopsy specimens
across a broad range of ethnicities at frequencies similar to what
we observed with our largely white cohort. Further evaluation of
the role of CD8 T cell selective pressure in sequence diversity is
necessary.
We observed a notable difference between the sequences of
LMP1 CTAR3 isolated from nasopharyngeal carcinoma tissue and
from our patient samples. This region exhibits the only amino acid
changes that are compartment specific in two different patients,
suggesting that CTAR3 may be under different pressures in differ-
ent compartments. The cytoplasmic region of LMP1 contains 2
JAK3 binding sites (PHDPLP) and a stretch of 11 amino acids
encoded by the so-called 33-bp repeat (aa 275 to 307) (68, 69).
Recent evidence has indicated that both of these regions are re-
quired for the recruitment of Ubc9, the E2 component of the
sumoylation cascade, as demonstrated by a general increase in the
levels of sumoylated proteins following LMP1 expression (70).
Additional research has shown that expression of a variant of
LMP1 lacking the Ubc9 interaction domain results in a decrease in
the level of sumoylation of interferon regulatory factor 7 (IRF7), a
transcription factor of type I interferon genes (71).
Interestingly, EBV LMP1 is capable of promoting multiple
modifications to IRF7, including ubiquitylation (both K48-
and K63-polyubiquitin chains) through ubiquitin ligase re-
cruitment, deubiquitylation through interaction with A20, and
sumoylation through interaction with Ubc9 (reviewed in ref-
erence 68). These modifications can affect IRF7 activity by
stimulating protein degradation, nuclear or cytoplasmic local-
ization, and chromatin binding, thus providing LMP1 with a
high degree of regulatory control over IRF7 function (68). It
has been proposed that LMP1 activity is critical for maintain-
ing EBV latency, and disruption of LMP1 function may lead to
oncogenesis (71). This theory seems to be supported by the
results of our sequencing analyses, which contrast the amino
acid sequences of LMP1 from samples derived from patients
with NPC or lymphoproliferative disorders with the LMP1 se-
quences from our own AIM cohort. As Fig. 6 illustrates, con-
sensus LMP1 sequences from AIM patients and from strain
B95-8 contain complete CTAR3, possessing both JAK3 binding
site motifs and a complete 11-amino-acid repeat. These LMP1
variants would be expected to regulate IRF7 activity tightly to
establish and maintain viral latency. In contrast, reference se-
quences assembled from NPC patient samples lack both fea-
tures and would thus be expected to have altered ability to
regulate IRF7. Determining the role of LMP1 mutations in
EBV-associated pathologies will require additional investiga-
tion into the full EBV genome, as well as the establishment of
longitudinal studies to ascertain whether the differences ob-
served in the LMP1 sequence predate the development of the
carcinoma or arise after a separate oncogenic event.
The observation that LMP1 is essential for EBV-induced
proliferation and transformation in vitro (40), along with the
fact that it induces nuclear factor B (NF-B) activity, has led
to the hypothesis that LMP1 polymorphisms may be associated
with the development of EBV-associated tumors. Zuercher et
al. (72) have reported several specific LMP1 polymorphisms in
blood and tumor viral sequences from HIV-infected patients
with Hodgkin lymphoma that are possibly associated with in-
creased NF-B activation. These included the single amino
acid changes F106Y, I124V, and F144I. I124V was not observed
in any of our study patients, but F106Y variants were found in
all nine study patients, and F144I variants were observed in five
of the nine study patients. The common detection of variants
associated with enhanced NF-B activation in the peripheral
blood of healthy individuals was somewhat surprising, al-
though it is possible that net NF-B activation may be modu-
lated by other polymorphisms.
For RNA viruses, next-generation sequencing has suggested
that minor viral variants, together with the diverse major variants,
evolve and impact disease progression (29, 32, 73). Likewise, the
minor variants may have biological relevance in DNA virus infec-
tions and pathogenesis. Here we have demonstrated an improved
sequencing methodology that has near 100% coverage and a depth
of as much as 130,000 times, allowing the detection of minor vari-
ants with a1% error rate. Defining virus population structures
based on genetic variation is advantageous in determining the
founder viruses and coinfecting or coresident viral variants and in
defining transmission chains. Additional studies using recently
reported methodologies to sequence whole viral genomes directly
from clinical samples (74, 75) will be critically important for iden-
tifying genetic variants associated with disease.
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